Across TCGA pan-cancer cohorts, NDUFB4P2 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of NDUFB4P2’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where NDUFB4P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NDUFB4P2 is over-expressed in tumor.
BRCA, COAD, and KIRC are the cancer types where NDUFB4P2 tumor–normal differential expression is most reproducible.